| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very bullish (overall 2.6, positive 2.9, negative -0.3) on 20251204. The forces of Sentiment towards Fundamentals (2.1), Option Sentiment (1.5), Valuation Sentiment (1.3), Broad Market Trend (0.4), Market Risk Appetite (0.4), and Price Level Sentiment (0) will drive up the price. The forces of and Sector Price Trend (-0.6) will drive down the price. 'Long' is the preferred trading strategy. The swing to upside will be significant considering the high positive sentiment forces (2.9). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Action | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-04 | 1% | 0.9% | 153.94 | 57 | -0.74% | 0.13% | 2.6 | -0.6 | Range | 2.1 | 0.5 |
| 2025-12-03 | 1% | 0.7% | 155.09 | 67 | 0.5% | 0.13% | 2.1 | -0.8 | Range | 2.1 | 4.1 |
| 2025-12-02 | 1% | 1% | 154.32 | 64 | -0.64% | 0.19% | 2.5 | -0.5 | Range | 2.1 | 5 |
| 2025-12-01 | 2% | 1% | 155.32 | 72 | -1.43% | 0.19% | 2.5 | 0.3 | Range | 2 | -0.1 |
| 2025-11-30 | 0% | 1.1% | 3.6 | 1 | Long | 1.9 | 1 | ||||
| 2025-11-29 | 1% | 1.3% | 3.4 | 1 | Long | 2 | 6 | ||||
| 2025-11-28 | 0% | 1.3% | 157.58 | 86 | -0.5% | 0.32% | 4.2 | 1 | Long | 2 | 1.5 |
| 2025-11-27 | 0% | 1.7% | 3.8 | 1 | Long | 2.3 | -1 | ||||
| 2025-11-26 | 3% | 2% | 158.37 | 95 | -0.25% | 0.39% | 3.9 | 1 | Range | 2.6 | 3 |
| 2025-11-25 | 1% | 1.7% | 158.76 | 103 | 2.26% | 0.52% | 4 | 1.8 | Range | 2.9 | 5.1 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. | Range refers to range trade strategy. In an uptrend, the price will likely bullback after huge advance. As an investor, you may want to wait for the pullback to open long position. As a trader, you may consider tactical short. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. As a trader, you may consider tactical long. |
| 1 (8) Humana And Mark Cuban’s Cost Plus Drugs Working On Partnership To Lower Prices The health insurance giant Humana and Mark Cuban’s Cost Plus Drugs are discussing ways to partner to lower the cost of prescription drugs for U.S. employers. (https://www.forbes.com/) Thu. Dec 4, 2025 | |
| 2 (8) An under-the-radar medical device stock with 20% upside, according to the charts Jay Woods breaks down the charts in Steris. (https://www.cnbc.com/) Thu. Dec 4, 2025 | |
| 3 (5) Humana Working With Mark Cuban on Potential Pharmacy Partnership Humana Inc. is working with billionaire Mark Cuban on a potential pharmacy partnership, Cuban and Humana’s chief executive officer said at a conference Thursday, a move that could step up pressure on larger pharmacy middlemen. (https://www.bloomberg.com/) Thu. Dec 4, 2025 | |
| 4 (-7) Philips CEO Warns About 2026 Growth Target, Stock Drops Philips shares tumble after the CEO signals slower growth, bigger tariff headwinds and no early guidance ahead of its 2026 outlook update. (https://www.benzinga.com/) Thu. Dec 4, 2025 | |
| 5 (0) Wegovy’s prices are going down, but they are ‘wildly different’ — and confusing How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average person to understand. (https://www.marketwatch.com/) Thu. Dec 4, 2025 | |
| 6 (-6) Moderate Republicans Defy House Leaders in Health Subsidy Bid The proposal faces an uphill climb as Republican congressional leaders dig in on opposition to renewing tax credits set to expire Dec. 31. More than 20 million Americans covered by Obamacare insurance policies on average will see their premiums more than double as a result. The plan, co-sponsored by Republican Jen Kiggans of Virginia and Democrat Josh Gottheimer of New Jersey, is backed by a bipartisan group of more than 30 House members, according to a statement from Gottheimer. (https://finance.yahoo.com/) Thu. Dec 4, 2025 | |
| 7 (-2) Wegovy’s prices are going down, but they are ‘wildly different’ — and confusing How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average person to understand. (https://www.marketwatch.com/) Thu. Dec 4, 2025 | |
| 8 (8) Medtronic Scores FDA Win As Hugo Surgical Robot Enters 230,000 Urology Procedure Market Medtronic's Hugo surgical robot gained FDA clearance for urologic procedures, opening U.S. market entry and setting the stage for expected sales growth in 2026. (https://www.benzinga.com/) Thu. Dec 4, 2025 | |
| 9 (-7) How Impoverished People Selling Their Blood Fuels Drug Profits Plasma-derived medicines that save millions of lives depend on supplies bought from America’s poorest. (https://www.bloomberg.com/) Thu. Dec 4, 2025 | |
| 10 (8) Prediction: 1 Healthcare Giant Set to Soar in 2026 Things are finally looking up for the company. (https://www.fool.com/) Thu. Dec 4, 2025 | |
| 11 (7) Up 37% Since August, Is It Safe to Buy UnitedHealth Group Stock Again? The health insurance giant's stock got a big boost after Wall Street learned Berkshire Hathaway had invested in it. (https://www.fool.com/) Wed. Dec 3, 2025 | |
| 12 (8) Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA review and VRDN-003 Phase 3 data. (https://www.benzinga.com/) Wed. Dec 3, 2025 | |
| 13 (7) A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why. Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome of a late-stage trial has been delayed. (https://www.marketwatch.com/) Wed. Dec 3, 2025 | |
| 14 (0) Companies Cut Prices For Blockbuster Weight-Loss Drugs In this week’s edition of InnovationRx, we look at the Forbes 30 Under 30 Healthcare list, the coming barriers to getting vaccines, and more. (https://www.forbes.com/) Wed. Dec 3, 2025 | |
| 15 (7) What's Going On With Bristol-Myers Squibb Shares Wednesday? Bristol-Myers Squibb shares gained after the company announced that it will enroll additional patients in the ADEPT-2 study. (https://www.benzinga.com/) Wed. Dec 3, 2025 | |
| 16 (0) 10 Health Care Stocks With Whale Alerts In Today's Session (https://www.benzinga.com/) Wed. Dec 3, 2025 | |
| 17 (7) Dow up nearly 150 points on gains for shares of UnitedHealth, McDonald's Buoyed by strong returns for shares of UnitedHealth and McDonald's, the Dow Jones Industrial Average is up Wednesday morning. Shares of UnitedHealth UnitedHealth Group Inc. and McDonald's McDonald's Corp. have contributed to the index's intraday rally, as the Dow Dow Jones Industrial Average was most recently trading 145 points, or 0.3%, higher. (https://www.marketwatch.com/) Wed. Dec 3, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA